

Characterization of Oxacillinase and Metallo- β -Lactamas Genes and Molecular Typing of Clinical Isolates of *Acinetobacter baumannii* in Ahvaz, South-West of Iran

Saeed Shoja,^{1,*} Mojtaba Moosavian,² Soodabeh Rostami,³ Fariba Abbasi,⁴ Mohammad Amin Tabatabaiefar,⁵ and Amir Peymani⁶

¹Infectious and Tropical Diseases Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, IR Iran

²Microbiology Department, Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran

³Nosocomial Infections Research Center, Isfahan University of Medical Sciences, Isfahan, IR Iran

⁴Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran

⁵Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran

⁶Microbiology Department, Qazvin University of Medical Sciences, Qazvin, IR Iran

*Corresponding author: Saeed Shoja, Infectious and Tropical Diseases Research Center, Hormozgan University of Medical Sciences, P. O. Box: 7919693116, Bandar Abbas, IR Iran. Tel: +98-7633668357, E-mail: shojaesaeed@gmail.com

Received 2015 August 14; Revised 2015 October 20; Accepted 2015 December 2.

Abstract

Background: Carbapenem resistant *Acinetobacter baumannii* is an important nosocomial pathogen associated with a variety of infections.

Objectives: The current study aimed to characterize the antimicrobial susceptibility, analyze the prevalence of oxacillinase and metallo- β -lactamase (MBL) genes and molecular typing of clinical isolates of *A. baumannii*.

Materials and Methods: A total of 124 non-repetitive isolates of *A. baumannii* were collected from various clinical specimens in two teaching hospitals in Ahvaz, south-west of Iran. Antimicrobial susceptibility test was carried out by disk diffusion method. The minimum inhibitory concentrations (MICs) of imipenem, meropenem, colistin and tigecycline were determined using E-test. To screen for MBL production, double disk synergy (DDs) test and MBL E-test were performed. The presence of *bla*_{OXA-23-like}, *bla*_{OXA-24-like}, *bla*_{OXA-51-like}, *bla*_{OXA-58-like}, *bla*_{VIM}, *bla*_{IMP} and *bla*_{SPM} genes was assessed by polymerase chain reaction (PCR). To identify clonal relatedness, all isolates were subjected to repetitive sequence-based PCR (rep-PCR)

Results: Based on disk diffusion results, the highest rate of resistance was observed in rifampin (96.8%). Colistin and polymyxin-B were the most effective agents in vitro. According to the MIC results, the rate of resistance to imipenem, meropenem, colistin and tigecycline were 78.2%, 73.4%, 0.8% and 0, respectively. Metallo- β -lactamase production was positive in 42.3% and 79.4% of the isolates by DDs test and E-test, respectively. All isolates (100%) carried *bla*_{OXA-51-like} gene. According to the results of multiplex PCR, *bla*_{OXA-23-like} and *bla*_{OXA-24-like} genes were detected in 85.6% and 6.2% of carbapenem resistant isolates, respectively. No *bla*_{OXA-58-like}, *bla*_{VIM}, *bla*_{IMP} and *bla*_{SPM} were detected. By rep-PCR, carbapenem resistant isolates were separated into six genotypes (A to F). Genotype A (30.9%) was the most prevalent (P value < 0.001). Genotypes B and C were found in 28.9% and 26.8% of the isolates, respectively.

Conclusions: The rate of carbapenem resistant *A. baumannii* isolates were high in this study. Since, *bla*_{OXA-58-like} or MBL genes were not detected, it seems that resistance to carbapenems is related to *bla*_{OXA-23-like} and *bla*_{OXA-24-like}. Moreover, *bla*_{OXA-23-like} was the most prevalent oxacillinase (OXA) gene. Most of the isolates belonged to one of the four dominant genotypes indicating clonal dissemination in the hospitals under study. In order to control the spread of carbapenem-resistant *A. baumannii*, infection-control strategies are needed.

Keywords: *Acinetobacter baumannii*, Carbapenems, Oxacillinase, Typing

1. Background

In recent years, *Acinetobacter baumannii* has emerged as an important pathogen in nosocomial infections and especially infects critically ill patients admitted to the intensive care units (ICUs) (1, 2). Septicemia, pneumonia, urinary tract infection, wound infection and meningitis are among the infections caused by this pathogen (3). In the hospital environment, resistance of *A. baumannii* to antimicrobial agents raises concerns (4). Carbapenem resistant *A. baumannii* are great concerns for physicians because carbapenems are common choice to treat infec-

tions caused by this pathogen (4, 5). In addition, therapeutic efficacy of carbapenems is limited due to spread of carbapenem resistant *A. baumannii* (4, 6). Carbapenem resistance is now observed worldwide in *A. baumannii* and these isolates are usually resistant to all classes of antimicrobial agents. A plenty of outbreak due to carbapenem resistant *A. baumannii* are reported from different countries and this situation had a worrying trend (4).

Carbapenem resistance in *A. baumannii* is mediated by combined different mechanisms including: reduced per-

meability, changes in penicillin binding protein, AmpC stable derepression, efflux pumps and mostly by production of oxacillinases (OXAs) and less common by metallo- β -lactamase (MBLs) genes (7-9). Clonal transmission of drug resistant *A. baumannii* is reported globally (10). Inter hospital transmission of carbapenem resistant *A. baumannii* is demonstrated (4). It is well documented that in the nosocomial outbreaks, in most of the cases, one or two epidemic clones are involved in a given hospital (4). For epidemiological purposes and to control the spread of resistant isolates, rapid differentiation of epidemic strains from the numerous incidental strains is necessary (11, 12). Molecular typing such as repetitive sequence-based polymerase chain reaction (rep-PCR) is required to determine the clonal relatedness of *A. baumannii* (12). The rep-PCR is beneficial for the molecular typing of *A. baumannii* (11).

2. Objectives

The current study aimed to determine the antimicrobial susceptibility pattern, prevalence and types of oxacillinase and metallo- β -lactamase genes and molecular typing by rep-PCR in the clinical isolates of *A. baumannii*.

3. Materials and Methods

3.1. Collection and Identification of *Acinetobacter baumannii* Isolates

From July 2011 to January 2013, a total of 124 non-duplicated *A. baumannii* isolates were collected from various clinical specimens in two teaching hospitals in Ahvaz, south-east of Iran. Bacterial isolates were initially identified as *A. baumannii* by biochemical tests (13). Suspected isolates were confirmed by PCR to identify *bla*_{OXA-51-like} gene with specific primers (listed in Table 1) to amplify a 353 base pair sequence (14). DNA template for PCR was obtained by boiling method (15). Each reaction was carried out in a final volume of 25 μ L containing 1x PCR buffer, 1 U Taq polymerase, 1.5 mM MgCl₂, 200 μ M of dNTP (SinaClon, Iran), 10 pmol of each primer (Eurofins MWG Operon, Germany) and 1 μ L of the extracted DNA. PCR conditions were programmed in Mastercycler Eppendorf (Eppendorf, Germany) as follows: Initial denaturation at 94°C for 3 minutes; 35 cycles of 94°C for 45 seconds, annealing 57°C for 45 seconds, extension 72°C for 1 minute and final extension 72°C for 5 minutes. PCR products were separated on 1.5% agarose gel (SinaClon, Iran) by electrophoresis, stained with ethidium bromide (SinaClon, Iran) and then visualized under UV illumination (Syngene GeneGenius gel documentation system). *Acinetobacter baumannii* ATCC 19606 was used as positive control (14).

3.2. Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing of all isolates was performed using Kirby-Bauer method according to the

clinical and laboratory standard institute (CLSI, 2011) guidelines. The following antimicrobial agents were tested: imipenem 10 μ g, meropenem 10 μ g, polymyxin-B 300 U, gentamicin 10 μ g, ceftaxime 30 μ g, colistin 10 μ g, piperacillin 100 μ g, piperacillin-tazobactam 100/10 μ g, cefepime 30 μ g, tobramycin 10 μ g, amikacin 30 μ g, tetracycline 30 μ g, ciprofloxacin 5 μ g, trimethoprim-sulfamethoxazole 1.25/23.75 μ g, ceftazidime 30 μ g, rifampin 5 μ g, tigecycline 15 μ g, aztreonam 30 μ g and ampicillin-sulbactam (10/10 μ g), (MAST, Group Ltd, Merseyside, UK). *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as control strains (20). Minimum inhibitory concentration (MIC) of imipenem, meropenem, colistin and tigecycline were determined by E-test strips (Liofilchem, Italy). Measures were obtained according to the CLSI guidelines. The US food and drug administration-approved criteria and Jones criteria were used for Enterobacteriaceae and tigecycline breakpoint, respectively (21, 22).

3.3. Screening the metallo- β -Lactamase Producing Isolates

All isolates were screened for MBL production by an imipenem-EDTA (ethylene diamine tetra-acetic acid) double disk synergy and E-test MBL. Briefly, an overnight culture suspension of each sample was adjusted to a turbidity equivalent to 0.5 McFarland and inoculated on the surface of a Mueller-Hinton agar plate. Two 10 μ g of imipenem disk (MAST, Group Ltd, Merseyside, UK) were placed on the plate 10 mm apart from edge to edge. Then 10 μ L of 0.5 M EDTA solution (SinaClon, Iran) was directly added to one of them to obtain the desired concentration (750 μ g). The plates were incubated at 35°C for 18 hours. After incubation, inhibition zones of the imipenem and imipenem-EDTA disks were measured and compared. If enlarged zone with imipenem-EDTA was 7 mm greater than the imipenem disk alone, it was considered as MBL positive revealing the inactivation of metallo- β -lactamase (class B) activity by EDTA (23, 24). Also an E-test MBL strip containing a double sided seven dilution range of imipenem (4 to 256 μ g/mL) and imipenem (1 to 64 μ g/mL) in combination with a fixed concentration of EDTA (Liofilchem, Italy) was used. The results were interpreted according to the manufacturer's instruction.

3.4. PCR Amplification of OXA and Metallo- β -Lactamase Genes

Multiplex PCR was performed to detect *bla*_{OXA-23-like}, *bla*_{OXA-24-like} and *bla*_{OXA-58-like} using specific primers as previously described (16). DNA template was obtained by boiling method (15). Each PCR reaction was performed in a final volume of 25 μ L with 1x PCR buffer, 1 U Taq polymerase, 2 mM MgCl₂, 200 μ M of dNTP (SinaClon, Iran), 0.2 μ M of each primer (TAG, Copenhagen A/S Denmark) and 1 μ L of template DNA. PCR conditions were programmed

in Mastercycler Eppendorf (Eppendorf, Germany) as follows: Initial denaturation at 94°C for 5 minutes; followed by 30 cycles at 94°C for 30 seconds, 53°C for 40 seconds and 72°C for 50 seconds and final extension at 72°C for 6 minutes. PCR products were separated by electrophoresis on 1.5% agarose gel (SinaClon, Iran) and after staining with ethidium bromide, visualized under UV gel documentation system *Acinetobacter baumannii* reference strains including: NCTC 13304, NCTC 13302, NCTC 13305 were used as positive control for *bla*_{OXA-23-like}, *bla*_{OXA-24-like} and *bla*_{OXA-58-like}, respectively (16). For each gene, one amplicon was sequenced (Bioneer, South Korea) *bla*_{VIM}, *bla*_{IMP} and *bla*_{SPM} were sought by singleplex PCR and primers previously described (17, 18). Two clinical isolates of *P. aeruginosa* harbored *bla*_{IMP} and *bla*_{VIM} were sequenced using automated sequence analyzer (Bioneer, South Korea) and used as positive control to identify the genes. The DNA of *bla*_{SPM}-positive *P. aeruginosa* was purchased from Pasteur Institute of Iran and used as positive control in PCR reactions.

3.5. The rep-PCR

To investigate genotyping and identification of various clones, all isolates were subjected to rep-PCR with emphasis on carbapenem resistant isolates. Specific primers were used according to the previously described Bou et al. protocol (19). Template for PCR was extracted by phenol-chloroform method. Each reaction mixture was done in the total volume of 25 µL with 1x PCR buffer, 3.5 mM of MgCl₂, 300 µM of dNTP, 3% dimethyl sulfoxide (DMSO) (SinaClon, Iran), 0.5 µM of each primer (TAG, Copenhagen A/S, Denmark), and 1U of Taq polymerase and 1 µL of genomic DNA. Amplification conditions were as follows: 94°C for 10 minutes; 30 cycles of 94°C for 1 minute, annealing temperatures 45°C for 1 minute, 72°C for 2 minutes and 72°C for 16 minutes. Products were separated by electrophoresis on 1.2% agarose gel (SinaClon, Iran); after staining with ethidium bromide, they were visualized under UV gel documentation system; then they were photographed and compared together by visual inspection (19). All fingerprints were observed by one observer. Snelling et al. protocol was used for classified various clones (11).

3.6. Nucleotide Sequence Accession Number

The nucleotide sequences obtained in this study were submitted to the GenBank nucleotide sequence database under the accession numbers: HG937619 for *bla*_{OXA-23-like}, HG937620 for *bla*_{OXA-24-like} and HG937621 for *bla*_{OXA-51-like}.

3.7. Statistical Analysis

The results were analyzed using the SPSS version 16 to obtain frequencies and comparison among clones. Non-parametric chi-square test was used. A P value < 0.05 was considered statistically significant.

4. Results

4.1. Bacterial Isolates

Totally, 124 single-patient isolates were recovered. All isolates were positive for *bla*_{OXA-51-like} and identified as *A. baumannii*. The rate of isolates from each ward and specimen are shown in Table 2.

4.2. Antimicrobial Susceptibility

The results of antimicrobial susceptibility test by disk diffusion method are shown in Table 3. Colistin and polymyxin-B were the most active agents against the tested isolates. According to the results of MICs by E-test, among 124 isolates, 97 (78.2%) were resistant to imipenem. However, meropenem resistance was observed in 91 (73.4%) of the studied isolates. Only one isolate (0.8%) was resistant to colistin and 123 isolates (98.2%) were susceptible to this antibiotic. No tigecycline resistant isolate was observed and 99 (79.8%) and 25 (20.2%) isolates were sensitive and intermediate to this antibiotic, respectively.

4.3. PCR Amplification of OXA Genes

Multiplex PCR analysis identified *bla*_{OXA-23-like} in 83 (85.6%) of carbapenem resistant isolates. Six isolates (6.2%) contained *bla*_{OXA-24-like} (Figure 1). All isolates were negative for *bla*_{OXA-58-like}. Eight isolates were carbapenem resistant but had only *bla*_{OXA-51-like} and other studied isolates were negative in the other studied genes. No amplification products were obtained in carbapenem susceptible isolates.

4.4. Metallo-β-Lactamase E-Test

To study the MBL production, carbapenem resistant isolates were evaluated by double disk synergy (DDS) test and E-test MBL strips. Of the 97 carbapenem resistant isolates, 41 (42.3%) exhibited a > 7 mm inhibitory zone and were categorized as MBL producer. However 56 isolates (57.7%) were negative for MBL production. Results of MBL E-test showed that among 97 carbapenem resistant isolates, 77 (79.4%) were positive for metallo-β-lactamase production and 20 isolates (20.6%) were negative (Figure 2). PCR did not detect metallo-β-lactamase genes, including *bla*_{VIM}, *bla*_{IMP} and *bla*_{SPM}, among the studied isolates.

4.5. REP PCR

Among carbapenem resistant isolates, six clones (A - F) were observed which three of them were more prevalent (Figure 3). Genotype A was the most prevalent (P value < 0.001) and 30.9% (30 isolates) belonged to this genotype. The prevalence of other genotypes were as follows: 28 isolates (28.9%) belonged to clone B, 26 isolates (26.8%) to clone C, 10 isolates (10.3%) to clone D and 2 isolates (2.1%) to clone E. Clone F contained only one isolate (1%). Carbapenem susceptible isolates (27 isolates) had unique genotypes.

Table 1. Sequence of Primers Used in the Study

Primer	Forward Sequence 5' - 3'	Reverse Sequence 5' - 3'	Reference
<i>bla</i> _{OXA-51-like}	TAATGCTTTGATCGGCCTTG	TGGATTGCACCTTCATCTTGG	(14)
<i>bla</i> _{OXA-23-like}	GATCGGATTGGAGAACCAGA	ATTCTGACCGCATTCCAT	(16)
<i>bla</i> _{OXA-24-like}	GGTTAGTTGGCCCCCTTAAA	AGTTGAGCGAAAAGGGGATT	(16)
<i>bla</i> _{OXA-58-like}	AAGTATTGGGGCTTGTGCTG	CCCCTGCGCTCTACATAC	(16)
<i>bla</i> _{IMP}	TCGTTGAAGAAGTTAACGG	ATGTAAGTTCAAGAGTGATGC	(17)
<i>bla</i> _{VIM}	GGTGTGGTGCATATCGCAA	ATTCAGCCAGATCGGCATCGGC	(17)
<i>bla</i> _{SPM}	AAAATCTGGGTACGCAAACG	ACATTATCCGCTGGAACAGG	(18)
REP	REP-I, III: GCGCCGICATCAGGC	REP-II: ACGTCTTATCAGGCCTAC	(19)

Table 2. The Rate of *Acinetobacter baumannii* Species Isolated From Each Ward and Specimen

Ward	Rate of Isolates	Specimen	Rate of Isolates
ICU	74.2	Tracheal aspirate	57.3
Out patients	8.1	Cerebrospinal fluid	11.3
Neurosurgery	4	wound	10.5
Dermatology	4	Urine	8.1
Nephrology	3.2	Discharge	5.6
Orthopedic	2.4	Blood	3.2
Woman	2.4	Pleura	1.6
Surgery	0.8	Catheter	1.6
Neonatal	0.8	Eye infection	0.8

Abbreviation: ICU, intensive care unit.

Table 3. The Results of Antibigram Analysis of *Acinetobacter baumannii* Isolates^a


Antibiotic	Sensitive	Intermediate	Resistant
Imipenem	24.2	1.6	74.2
Meropenem	19.4	0.8	79.8
Ceftazidime	15.3	2.4	82.3
Cefepime	16.1	4	79.8
Ceftriaxone	1.6	12.1	86.3
Colistin	98.2	NA	0.8
Piperacillin	12.1	3.2	84.7
Piperacillin-tazobactam	16.9	1.6	81.5
Polymyxin-B	100	NA	NA
Gentamicin	28.2	4.8	66.9
Tobramycin	33.9	1.6	64.5
Amikacin	21	12.1	66.9
Tetracycline	21.8	12.1	66.1
Ampicillin-sulbactam	32.3	21.8	46
Ciprofloxacin	13.7	1.6	84.7
Trimethoprim-sulfamethoxazole	19.4	4.8	75.8
Rifampin	NA	3.2	96.8
Aztreonam	NA	4.8	95.2
Tigecycline (FDA)	6.5	58.1	35.5
Tigecycline (Jones)	45.2	50.8	4

Abbreviation: NA, not available.


^aValues are expressed as %.

Figure 1. Agarose gel Showing OXAs Genes Obtained by Multiplex PCR

Lanes 1 and 12, 100 bp DNA ladder; lanes 2, 3 and 9, isolates with *bla*_{OXA-24-like} in 249 bp; lanes 4 - 8, isolates with *bla*_{OXA-23-like} in 501bp; lane 10, negative control (distilled water). lane 11, positive control *Acinetobacter baumannii* NCTC 13304, NCTC 13302 and NCTC 13305 were used as positive controls for *bla*_{OXA-23-like}, *bla*_{OXA-24-like} and *bla*_{OXA-58-like}, respectively.

Figure 2. A MBL Producer *Acinetobacter baumannii* Isolate

An inhibitory zone is observed in Imipenem + EDTA compared to that of imipenem only.

Figure 3. An Agarose gel rep-PCR Product for the Resistant Isolates

For each clone, double fingerprints are shown. Lanes 1, 6, and 13, 1 kb DNA ladder; lanes 2 and 3, clone A; lanes 4, 5, clone B; lanes 7 and 8, clone C; lane 9 and 10, clone D; lane 11, negative control; lane 12, *A. baumannii* NCTC 12156 (ATCC 19606).

5. Discussion

In the current study most of the isolates (74.2%) were obtained from patients in ICUs and in accordance to other researches worldwide, the rate of infection caused by *A. baumannii* is high in ICUs (25, 26). Previously, it was reported that *A. baumannii* is more prevalent among endotracheal aspirate samples. Moreover, ventilator associated pneumonia is one of the frequent nosocomial infections caused by this organism (27-31). In accordance to the mentioned studies, most of the current study samples (57.3%) were isolated from tracheal aspirates. In the present study, antimicrobial susceptibility pattern showed that colistin and polymyxin-B are the most effective agents against *A. baumannii* isolates, *in vitro*. Colistin is the last line antimicrobial agent to treat multidrug resistant *A. baumannii* (26, 32). Although, colistin resistant isolates are reported globally (32), in the current study only 0.8% of isolates were colistin resistant.

This result indicates that colistin can be used to treat *A. baumannii* infections in the studied hospitals. Afterwards, among the tested antimicrobial agents, the highest rate of resistance was observed against rifampin; 96.8% and 3.2% of the isolates were resistant and intermediate to this antibiotic, respectively. No isolate was sensitive to rifampin; hence, it is suggested that rifampin might be ineffective to treat *A. baumannii* infections in the studied hospitals. Carbapenems are successfully used to treat multidrug resistant *A. baumannii* infections; however, in recent years increase of carbapenem resistant *A. baumannii* isolates compromised their use (4, 26, 33). The emergence of carbapenem resistant *A. baumannii* is a global concern (4). In the current study the rates of resistance to imipenem by E-test and disk diffusion method were 78.2% and 74.2%, respectively. In addition, 79.8% and 73.4% of the isolates were resistant to meropenem by disk diffusion and E-test, respectively.

There is a discrepancy between carbapenems E-test and disk diffusion method. Based on E-test, 78.2% of the isolates were resistant to imipenem; while disk diffusion method showed that 74.2% of the isolates were resistance to imipenem. In contrast, meropenem E-test detected 73.4% of isolates as resistant; whilst, according to disk diffusion more isolates (79.8%) were recorded as meropenem resistant. However, authors could not elucidate this difference. In *A. baumannii*, the most common carbapenemase genes involved in carbapenem resistance are, *bla*_{OXA-23-like}, *bla*_{OXA-24-like}, *bla*_{OXA-58-like} and *bla*_{OXA-143-like} (26, 34). In the current study, multiplex PCR detected 85.6% of carbapenem resistant isolates carrying *bla*_{OXA-23-like}. The spread of OXA genes varies in different parts of the world and *bla*_{OXA-23-like} is reported from 31% to 94% (7, 12, 35-39). The current study found that 6.2% of carbapenem resistant isolates harbor *bla*_{OXA-24-like}.

Some authors worldwide, reported the rate of *bla*_{OXA-24-like} from 0 to 85.43% (7, 33, 36, 38-40). The results of the current study were consistent with those of other

studies and the findings for *bla*_{OXA-23-like} and *bla*_{OXA-24-like} were in the reported ranges. In contrast to other studies that reported the range of *bla*_{OXA-58-like} from 2% to 84.92% (12, 35-38, 40), the current study could not find any isolates positive for *bla*_{OXA-58-like}. Albeit the reported co-existence of OXAs genes (29, 41, 42), coexistence between these genes was not observed in the current study and all *A. baumannii* isolates only had one of the *bla*_{OXA-23-like} or *bla*_{OXA-24-like} genes. In the current study, 42.3% and 79.4% of the isolates were MBL positive by DDs test and MBL E-test, respectively. Despite phenotypic tests, no *bla*_{IMP}, *bla*_{VIM} and *bla*_{SPM} genes were detected by PCR and the isolates were negative for these genes.

There are some possibilities about this phenomenon: 1) the MBL production may be false positive and due to bactericidal activity of EDTA, which may result in increased inhibitory zone and not associated with true MBL production (43); 2) MBL production may be true positive due to other MBL genes such as *bla*_{NDM} that were not investigated in the current study (44). Similar results are reported that *A. baumannii* isolates were MBL producer by phenotypic tests but no MBL encoding genes were detected (45, 46). It is reported that MBL E-test has good sensitivity for MBL detection and could detect MBL both chromosomally and plasmid mediated in aerobic and anaerobic bacteria (47).

According to the E-test results, it is possible that the current study isolates were true MBL producers. Interestingly the study found eight carbapenem resistant isolates that were negative for *bla*_{OXA-23-like}, *bla*_{OXA-24-like}, *bla*_{OXA-58-like} and MBL genes and only harbored *bla*_{OXA-51-like}. Similarly, Nowak et al. reported that seven isolates of carbapenem resistant *A. baumannii* only had *bla*_{OXA-51-like} (29). Carbapenem resistance in these isolates may be associated with other mechanisms such as: modification of penicillin binding proteins, loss of porins and decreased permeability, AmpC stable derepression or over expression of efflux pump (4, 8, 9).

It is noteworthy that, insertion of ISAbal in upstream of *bla*_{OXA-51-like} can lead to carbapenem resistance in *A. baumannii* (48). The relationship between harboring *bla*_{OXA-51-like} and resistance to carbapenem in the eight isolates still need to be investigated.

The current study also aimed to investigate the clonality of *A. baumannii* isolates by rep-PCR. Genotypic comparison by rep-PCR revealed that carbapenem resistant isolates belonged to six clones. All clones were spread in the ICUs. Clone A was dominant (30.9%) and clone F had the lowest prevalence (1%). Clonal dissemination of carbapenem resistant *A. baumannii* was previously reported in different studies. It has been established that multidrug resistant *A. baumannii* isolates with similar genotype can disseminate among various wards, different hospitals and even among cities (4, 10, 12, 49-51).

In the current study, the vast majority of carbapenem resistant isolates (94/97, 96.9%) belonged to one of the four dominant genotypes indicating clonal dissemination

of resistant isolates in the studied hospitals.

In conclusion, overall, the rate of carbapenem resistant isolates were high in the studied hospitals. Colistin and polymyxin-B were the effective antimicrobial agents, in vitro. Since in the current study *bla*_{OXA-58-like} or MBL genes were not detected, it seems that carbapenem resistance is mostly related to *bla*_{OXA-23-like} and *bla*_{OXA-24-like}, and these genes may play an important role in carbapenem resistance in the isolates. In addition, four clones of carbapenem resistant *A. baumannii* isolates are disseminated in the two studied hospitals and clone A was dominant. In accordance to other studies, in the current investigation most of the resistant isolates belonged to four clones indicating clonal dissemination of *A. baumannii* in the studied hospitals and that effective infection control strategies are necessary to control the spread of these resistant isolates.

Acknowledgments

This work was a part of PhD thesis, which was granted (No. 90126) and financially supported by deputy vice-chancellor for research affairs of Ahvaz Jundishapur University of Medical Sciences, and infectious and tropical diseases research center.

Footnotes

Authors' Contribution: Study concept and design: Saeed Shoja, and Mojtaba Moosavian; acquisition of data: Saeed Shoja, and Soodabeh Rostami; analysis and interpretation of data: Saeed Shoja and Mohammad Amin Tabatabaiefar; drafting of the manuscript: Mojtaba Moosavian and Amir Peymani; critical revision of the manuscript for important intellectual content: Saeed Shoja, and Mojtaba Moosavian; statistical analysis: saeed shoja and Amir Peymani; administrative, technical, and material support: Saeed Shoja, Mojtaba Moosavian and Fariba Abbasi; study supervision: Saeed Shoja, and Mojtaba Moosavian.

Funding/Support: This work was a part of PhD thesis, which was granted (No. 90126) and financially supported by deputy vice-chancellor for research affairs of Ahvaz Jundishapur University of Medical Sciences, and Infectious and tropical disease research center.

References

- Zarrilli R, Pournaras S, Giannouli M, Tsakris A. Global evolution of multidrug-resistant *Acinetobacter baumannii* clonal lineages. *Int J Antimicrob Agents*. 2013;41(1):11-9. doi: 10.1016/j.ijantimicag.2012.09.008. [PubMed: 23127486]
- Karah N, Haldorsen B, Hermansen NO, Tveten Y, Ragnhildstveit E, Skutlaberg DH, et al. Emergence of OXA-carbapenemase- and 16S rRNA methylase-producing international clones of *Acinetobacter baumannii* in Norway. *J Med Microbiol*. 2011;60(Pt 4):515-21. doi: 10.1099/jmm.0.028340-0. [PubMed: 21163830]
- Moosavian M, Shoja S, Nashibi R, Ebrahimi N, Tabatabaiefar MA, Rostami S, et al. Post Neurosurgical Meningitis due to Colistin Heteroresistant *Acinetobacter baumannii*. *Jundishapur J Microbiol*. 2014;7(10):e12287. doi: 10.5812/jjm.12287. [PubMed: 25632326]
- Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapene-

- nem resistance in *Acinetobacter baumannii*: the molecular epidemic features of an emerging problem in health care facilities. *J Infect Dev Ctries*. 2009;**3**(5):335–41. [PubMed: 19759502]
5. Dai W, Huang S, Sun S, Cao J, Zhang L. Nosocomial spread of carbapenem-resistant *Acinetobacter baumannii* (types ST75 and ST137) carrying blaOXA-23-like gene with an upstream ISAbal in a Chinese hospital. *Infect Genet Evol*. 2013;**14**:98–101. doi: 10.1016/j.meegid.2012.11.007. [PubMed: 23219422]
 6. Bogaerts P, Cuzon G, Naas T, Bauraing C, Deplano A, Lisois B, et al. Carbapenem-resistant *Acinetobacter baumannii* isolates expressing the blaOXA-23 gene associated with ISAb4 in Belgium. *Antimicrob Agents Chemother*. 2008;**52**(11):4205–6. doi: 10.1128/AAC.01121-08. [PubMed: 18765689]
 7. Irfan S, Turton JF, Mehraj J, Siddiqui SZ, Haider S, Zafar A, et al. Molecular and epidemiological characterisation of clinical isolates of carbapenem-resistant *Acinetobacter baumannii* from public and private sector intensive care units in Karachi, Pakistan. *J Hosp Infect*. 2011;**78**(2):143–8. doi: 10.1016/j.jhin.2011.01.029. [PubMed: 21459477]
 8. Kulah C, Mooij MJ, Comert F, Aktas E, Celebi G, Ozlu N, et al. Characterisation of carbapenem-resistant *Acinetobacter baumannii* outbreak strains producing OXA-58 in Turkey. *Int J Antimicrob Agents*. 2010;**36**(2):114–8. doi: 10.1016/j.ijantimicag.2010.03.017. [PubMed: 20510587]
 9. Poirel L, Nordmann P. Carbapenem resistance in *Acinetobacter baumannii*: mechanisms and epidemiology. *Clin Microbiol Infect*. 2006;**12**(9):826–36. doi: 10.1111/j.1469-0691.2006.01456.x. [PubMed: 16882287]
 10. van Dessel H, Dijkshoorn L, van der Reijden T, Bakker N, Paauw A, van den Broek P, et al. Identification of a new geographically widespread multidrug-resistant *Acinetobacter baumannii* clone from European hospitals. *Res Microbiol*. 2004;**155**(2):105–12. doi: 10.1016/j.resmic.2003.10.003. [PubMed: 14990262]
 11. Snelling AM, Gerner-Smidt P, Hawkey PM, Heritage J, Parnell P, Porter C, et al. Validation of use of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for typing strains belonging to the *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex and application of the method to the investigation of a hospital outbreak. *J Clin Microbiol*. 1996;**34**(5):1193–202. [PubMed: 8727902]
 12. Yan ZQ, Shen DX, Cao JR, Chen R, Wei X, Liu LP, et al. Susceptibility patterns and molecular epidemiology of multidrug-resistant *Acinetobacter baumannii* strains from three military hospitals in China. *Int J Antimicrob Agents*. 2010;**35**(3):269–73. doi: 10.1016/j.ijantimicag.2009.10.016. [PubMed: 20036519]
 13. Koneman EW. *Color atlas and textbook of diagnostic microbiology*. Lippincott-Raven Publishers;1997.
 14. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of *Acinetobacter baumannii* by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. *J Clin Microbiol*. 2006;**44**(8):2974–6. doi: 10.1128/JCM.01021-06. [PubMed: 16891520]
 15. Andriamanantena TS, Ratsima E, Rakotonirina HC, Randrianirina F, Ramparany L, Carod JF, et al. Dissemination of multidrug resistant *Acinetobacter baumannii* in various hospitals of Antananarivo Madagascar. *Ann Clin Microbiol Antimicrob*. 2010;**9**:17. doi: 10.1186/1476-0711-9-17. [PubMed: 20591154]
 16. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. *Int J Antimicrob Agents*. 2006;**27**(4):351–3. doi: 10.1016/j.ijantimicag.2006.01.004. [PubMed: 16564159]
 17. Zong Z, Lu X, Valenzuela JK, Partridge SR, Iredell J. An outbreak of carbapenem-resistant *Acinetobacter baumannii* producing OXA-23 carbapenemase in western China. *Int J Antimicrob Agents*. 2008;**31**(1):50–4. doi: 10.1016/j.ijantimicag.2007.08.019. [PubMed: 18077141]
 18. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn Microbiol Infect Dis*. 2011;**70**(1):119–23. doi: 10.1016/j.diagmicrobio.2010.12.002. [PubMed: 21398074]
 19. Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. PCR-based DNA fingerprinting (REP-PCR, AP-PCR) and pulsed-field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant *Acinetobacter baumannii*. *Clin Microbiol Infect*. 2000;**6**(12):635–43. [PubMed: 11284921]
 20. Wayne P. *Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 21st informational supplement M100-S21*. Wayne: CLSI; 2011.
 21. Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS. Multicenter studies of tigecycline disk diffusion susceptibility results for *Acinetobacter* spp. *J Clin Microbiol*. 2007;**45**(1):227–30. doi: 10.1128/JCM.01588-06. [PubMed: 17093026]
 22. Pharmaceuticals W. *Tyagcil (tigecycline) for injection [package insert]*. Philadelphia: Wyeth Pharmaceuticals Inc; 2005.
 23. Sung JY, Kwon KC, Park JW, Kim YS, Kim JM, Shin KS, et al. Dissemination of IMP-1 and OXA type beta-lactamase in carbapenem-resistant *Acinetobacter baumannii*. *Korean J Lab Med*. 2008;**28**(1):16–23. doi: 10.3343/kjlm.2008.28.1.16. [PubMed: 18309251]
 24. Jeon BC, Jeong SH, Bae IK, Kwon SB, Lee K, Young D, et al. Investigation of a nosocomial outbreak of imipenem-resistant *Acinetobacter baumannii* producing the OXA-23 beta-lactamase in Korea. *J Clin Microbiol*. 2005;**43**(5):2241–5. doi: 10.1128/JCM.43.5.2241-2245.2005. [PubMed: 15872249]
 25. Fontana C, Favaro M, Minelli S, Bossa MC, Testore GP, Leonardis F, et al. *Acinetobacter baumannii* in intensive care unit: a novel system to study clonal relationship among the isolates. *BMC Infect Dis*. 2008;**8**:79. doi: 10.1186/1471-2334-8-79. [PubMed: 18538034]
 26. Kempf M, Rolain JM. Emergence of resistance to carbapenems in *Acinetobacter baumannii* in Europe: clinical impact and therapeutic options. *Int J Antimicrob Agents*. 2012;**39**(2):105–14. doi: 10.1016/j.ijantimicag.2011.10.004. [PubMed: 22113193]
 27. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol*. 2007;**5**(12):939–51. doi: 10.1038/nrmicro1789. [PubMed: 18007677]
 28. Peymani A, Farajnia S, Nahaei MR, Sohrabi N, Abbasi L, Ansari K, et al. Prevalence of class 1 integron among multidrug-resistant *Acinetobacter baumannii* in Tabriz, northwest of Iran. *Pol J Microbiol*. 2012;**61**(1):57–60. [PubMed: 22708347]
 29. Nowak P, Paluchowska P, Budak A. Distribution of blaOXA genes among carbapenem-resistant *Acinetobacter baumannii* nosocomial strains in Poland. *New Microbiol*. 2012;**35**(3):317–25. [PubMed: 22842601]
 30. Shoja S, Moosavian M, Peymani A, Tabatabaiefar MA, Rostami S, Ebrahimi N. Genotyping of carbapenem resistant *Acinetobacter baumannii* isolated from tracheal tube discharge of hospitalized patients in intensive care units, Ahvaz, Iran. *Iran J Microbiol*. 2013;**5**(4):315–22. [PubMed: 25848498]
 31. Altun HU, Yagci S, Bulut C, Sahin H, Kinikli S, Adiloglu AK, et al. Antimicrobial Susceptibilities of Clinical *Acinetobacter baumannii* Isolates With Different Genotypes. *Jundishapur J Microbiol*. 2014;**7**(12):e13347. doi: 10.5812/jjm.13347. [PubMed: 25741433]
 32. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of *Acinetobacter baumannii*: clinical reports, mechanisms and antimicrobial strategies. *J Antimicrob Chemother*. 2012;**67**(7):1607–15. doi: 10.1093/jac/dks084. [PubMed: 22441575]
 33. Manageiro V, Jones-Dias D, Ferreira E, Louro D. Antimicrobial Resistance Surveillance Program in P, Canica M. Genetic diversity and clonal evolution of carbapenem-resistant *Acinetobacter baumannii* isolates from Portugal and the dissemination of ST118. *Int J Antimicrob Agents*. 2012;**40**(5):398–403. doi: 10.1016/j.ijantimicag.2012.06.013. [PubMed: 22890192]
 34. D'Arezzo S, Principe L, Capone A, Petrosillo N, Petrucca A, Visca P. Changing carbapenemase gene pattern in an epidemic multidrug-resistant *Acinetobacter baumannii* lineage causing multiple outbreaks in central Italy. *J Antimicrob Chemother*. 2011;**66**(1):54–61. doi: 10.1093/jac/dkq407. [PubMed: 21088019]
 35. Merkier AK, Catalano M, Ramirez MS, Quiroga C, Orman B, Ratier L, et al. Polyclonal spread of bla(OXA-23) and bla(OXA-58) in *Acinetobacter baumannii* isolates from Argentina. *J Infect Dev Ctries*. 2008;**2**(3):235–40. [PubMed: 19738357]
 36. Sohrabi N, Farajnia S, Akhli MT, Nahaei MR, Naghili B, Peymani A, et

- al. Prevalence of OXA-type beta-lactamases among *Acinetobacter baumannii* isolates from Northwest of Iran. *Microb Drug Resist*. 2012;**18**(4):385-9. doi: 10.1089/mdr.2011.0077. [PubMed: 22352411]
37. Touati M, Diene SM, Racherache A, Dekhil M, Djahoudi A, Rolain JM. Emergence of blaOXA-23 and blaOXA-58 carbapenemase-encoding genes in multidrug-resistant *Acinetobacter baumannii* isolates from University Hospital of Annaba, Algeria. *Int J Antimicrob Agents*. 2012;**40**(1):89-91. doi: 10.1016/j.ijantimicag.2012.03.017. [PubMed: 22580030]
 38. Ergin A, Hascelik G, Eser OK. Molecular characterization of oxacillinases and genotyping of invasive *Acinetobacter baumannii* isolates using repetitive extragenic palindromic sequence-based polymerase chain reaction in Ankara between 2004 and 2010. *Scand J Infect Dis*. 2013;**45**(1):26-31. doi: 10.3109/00365548.2012.708782. [PubMed: 22978782]
 39. Carvalho KR, Carvalho-Assef AP, Peirano G, Santos LC, Pereira MJ, Asensi MD. Dissemination of multidrug-resistant *Acinetobacter baumannii* genotypes carrying bla(OXA-23) collected from hospitals in Rio de Janeiro, Brazil. *Int J Antimicrob Agents*. 2009;**34**(1):25-8. doi: 10.1016/j.ijantimicag.2008.12.009. [PubMed: 19216059]
 40. Ben RJ, Yang MC, Hsueh JC, Shiang JC, Chien ST. Molecular characterisation of multiple drug-resistant *Acinetobacter baumannii* isolates in southern Taiwan. *Int J Antimicrob Agents*. 2011;**38**(5):403-8. doi: 10.1016/j.ijantimicag.2011.05.014. [PubMed: 21871784]
 41. Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, et al. Antimicrobial susceptibility patterns and distribution of blaOXA genes among *Acinetobacter* spp. Isolated from patients at Tehran hospitals. *Jpn J Infect Dis*. 2008;**61**(4):274-8. [PubMed: 18653968]
 42. Asadollahi K, Alizadeh E, Akbari M, Taherikalani M, Niakan M, Maleki A, et al. The role of bla(OXA-like carbapenemase) and their insertion sequences (ISS) in the induction of resistance against carbapenem antibiotics among *Acinetobacter baumannii* isolates in Tehran hospitals. *Roum Arch Microbiol Immunol*. 2011;**70**(4):153-8. [PubMed: 22568262]
 43. Chu YW, Cheung TK, Ngan JY, Kam KM. EDTA susceptibility leading to false detection of metallo-beta-lactamase in *Pseudomonas aeruginosa* by Etest and an imipenem-EDTA disk method. *Int J Antimicrob Agents*. 2005;**26**(4):340-1. doi: 10.1016/j.ijantimicag.2005.07.004. [PubMed: 16139483]
 44. Hrabak J, Stolbova M, Studentova V, Fridrichova M, Chudackova E, Zemlickova H. NDM-1 producing *Acinetobacter baumannii* isolated from a patient repatriated to the Czech Republic from Egypt, July 2011. *Euro Surveill*. 2012;**17**(7). [PubMed: 22370014]
 45. Purohit M, Mendiratta DK, Deotale VS, Madhan M, Manoharan A, Narang P. Detection of metallo-beta-lactamases producing *Acinetobacter baumannii* using microbiological assay, disc synergy test and PCR. *Indian J Med Microbiol*. 2012;**30**(4):456-61. doi: 10.4103/0255-0857.103770. [PubMed: 23183473]
 46. Hu Q, Hu Z, Li J, Tian B, Xu H, Li J. Detection of OXA-type carbapenemases and integrons among carbapenem-resistant *Acinetobacter baumannii* in a teaching hospital in China. *J Basic Microbiol*. 2011;**51**(5):467-72. doi: 10.1002/jobm.201000402. [PubMed: 21656808]
 47. Walsh TR, Bolmstrom A, Qvarnstrom A, Gales A. Evaluation of a new Etest for detecting metallo-beta-lactamases in routine clinical testing. *J Clin Microbiol*. 2002;**40**(8):2755-9. [PubMed: 12149325]
 48. Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, et al. The role of ISAbal in expression of OXA carbapenemase genes in *Acinetobacter baumannii*. *FEMS Microbiol Lett*. 2006;**258**(1):72-7. doi: 10.1111/j.1574-6968.2006.00195.x. [PubMed: 16630258]
 49. Peymani A, Farajnia S, Nahaei MR, Sohrabi N, Abbasi L. Clonal Characterization of Multidrug-Resistant *A. baumannii* Isolated from Imam Reza Hospital in Tabriz, Iran. *Iran J Infect Dis Trop Med*. 2012;**17**(58): 7-12.
 50. Kraniotaki E, Manganelli R, Platsouka E, Grossato A, Paniara O, Palu G. Molecular investigation of an outbreak of multidrug-resistant *Acinetobacter baumannii*, with characterisation of class 1 integrons. *Int J Antimicrob Agents*. 2006;**28**(3):193-9. doi: 10.1016/j.ijantimicag.2006.04.016. [PubMed: 16904293]
 51. Ece G, Erac B, Yurday Cetin H, Ece C, Baysak A. Antimicrobial Susceptibility and Clonal Relation Between *Acinetobacter baumannii* Strains at a Tertiary Care Center in Turkey. *Jundishapur J Microbiol*. 2015;**8**(2):e15612. doi: 10.5812/jjm.15612. [PubMed: 25825641]